secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001558370-25-003922
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path Holdings FY2024 net loss $9.9M; cash $1.2M; clinical progress in obesity and AML
--------------------------------------------------------------------------------

- Net loss of $9.9M ($4.12 per share) vs $16.1M ($33.63 per share) in FY2023.
- Cash and cash equivalents of $1.2M as of Dec 31, 2024; net cash used in operations $10.6M.
- R&D expense decreased to $7.3M from $11.6M; G&A expense increased to $4.7M.
- Preclinical BP1001-A shows restored insulin sensitivity; Phase 1/1b BP1002 in AML progressed to 90 mg/m² dose cohort.
- Patent portfolio expanded: 7 US patents, 61 foreign patents; new patents in US and NZ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837025003922/0001558370-25-003922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837025003922/bpth-20250328x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer